Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REACH3: ruxolitinib versus best available therapy for steroid-refractory chronic graft-versus-host disease
MOH_2017-06-11_000437Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ruxolitinib in chronic graft-versus-host disease (cGVHD) and graft-versus-host disease (GVHD) (2 arms), sponsored by Novartis. Started Jun 2017; status: completed.
02
Drugs
03
Conditions
chronic graft-versus-host disease (cGVHD)graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on MOH_2017-06-11_000437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-06-11_000437.